Pamidronate
Aredia · Bisphosphonate
Collapsing FSGS — first drug ever linked.
Intron A · Roferon-A · IFN
Cytokine · approved 1986 · 8 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A podocyte poison — the classic trigger of collapsing FSGS in APOL1 carriers.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Rare; best characterized by an 11-case biopsy series, disproportionately in Black patients (APOL1).Source: Markowitz et al., CJASN 2010
Develops over weeks to months of therapy.
Distilled from: “Subacute — weeks to months of therapy.”
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Immunomodulatory, antiproliferative cytokine. Historically melanoma, renal cell, CML and Kaposi sarcoma.
Glomerulus
Filtration barrier (podocytes + endothelium)
Class-level context for the major non-renal toxicities of the Cytokine class.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
5 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Interferon-α sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Aredia · Bisphosphonate
Collapsing FSGS — first drug ever linked.
Fruzaqla · VEGFR TKI
2023 colorectal VEGFR-TKI; hypertension and proteinuria, class effect.
Mutamycin · Antitumor antibiotic
Prototype dose-dependent TMA.
Velcade · Proteasome inhibitor
Rare TMA; reverses myeloma cast nephropathy.
Sprycel · BCR-ABL TKI
Nephrotic-range proteinuria — a notable signal.
Zaltrap · VEGF trap
Hypertension and proteinuria like bevacizumab.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Interferon-α’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Interferon-α; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 131 clinical records among the 300 most-relevant of 340 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.